BIOMARIN PHARMACEUTICAL INC false 0001048477 0001048477 2024-01-05 2024-01-05

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): January 5, 2024

 

 

BioMarin Pharmaceutical Inc.

(Exact name of Registrant as Specified in Its Charter)

 

 

 

Delaware   000-26727   68-0397820

(State or Other Jurisdiction

of Incorporation)

  

(Commission

File Number)

  

(IRS Employer

Identification No.)

 

770 Lindaro Street, San Rafael,

California

     94901
(Address of Principal Executive Offices)     (Zip Code)

Registrant’s Telephone Number, Including Area Code: (415) 506-6700

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

  ☐

Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

  ☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

  ☐

Pre-commencement communication pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

  ☐

Pre-commencement communication pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

  

Trading

Symbol(s)

  

Name of each exchange

on which registered

Common Stock, $0.001 par value   BMRN   The Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On January 11, 2024, BioMarin Pharmaceutical Inc. (“BioMarin” or the “Company”) announced that Mr. Jeffrey Ajer would step down as the Company’s Executive Vice President and Chief Commercial Officer, effective July 1, 2024. Mr. Ajer’s compensation will remain unchanged through that date. The separation will constitute a termination of employment by the Company without cause under Mr. Ajer’s Amended and Restated Employment Agreement dated June 10, 2015 (the “Employment Agreement”), and as such, Mr. Ajer will be entitled to receive severance pursuant to the Employment Agreement.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

   

BioMarin Pharmaceutical Inc.,

a Delaware corporation

Date: January 11, 2024     By:  

/s/ G. Eric Davis

     

G. Eric Davis

Executive Vice President, Chief Legal Officer

v3.23.4
Document and Entity Information
Jan. 05, 2024
Cover [Abstract]  
Entity Registrant Name BIOMARIN PHARMACEUTICAL INC
Amendment Flag false
Entity Central Index Key 0001048477
Document Type 8-K
Document Period End Date Jan. 05, 2024
Entity Incorporation State Country Code DE
Entity File Number 000-26727
Entity Tax Identification Number 68-0397820
Entity Address, Address Line One 770 Lindaro Street
Entity Address, City or Town San Rafael
Entity Address, State or Province CA
Entity Address, Postal Zip Code 94901
City Area Code (415)
Local Phone Number 506-6700
Written Communications false
Soliciting Material false
Pre Commencement Tender Offer false
Pre Commencement Issuer Tender Offer false
Security 12b Title Common Stock, $0.001 par value
Trading Symbol BMRN
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
BioMarin Pharmaceutical (NASDAQ:BMRN)
Historical Stock Chart
Von Apr 2024 bis Mai 2024 Click Here for more BioMarin Pharmaceutical Charts.
BioMarin Pharmaceutical (NASDAQ:BMRN)
Historical Stock Chart
Von Mai 2023 bis Mai 2024 Click Here for more BioMarin Pharmaceutical Charts.